Our Team
Fund Management –
Dr Reinhard J. Ambros is Global Head of Novartis Venture Fund, in Basel, Switzerland. Previously, he was Managing Director of the Novartis BioVenture Fund in the USA. He also worked with Novartis Corporate Finance where he held the position of Head of Group Strategic Planning for several years. He was responsible for post-merger integrations at Novartis Corporate M&A and was Global Head Business Development & Licensing for cardiovascular and metabolic diseases at Novartis Pharmaceuticals. Earlier in his career he had global leadership positions for key drug development projects at Novartis and Roche. He trained as a pharmacist, has a PhD in medicinal chemistry and pharmacology and focused postdoctoral training in clinical pharmacology.
Portfolio companies
Aileron Therapeutics, Inc. (Board Seat) Forma Therapeutics, LLC. (Board Seat) Genedata AG (Board Seat) Symetis AG (Board Seat) Aerpio Therapeutics, Inc. (Board Seat)
Exits
EsbaTech AG (Acquired by Alcon) Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) Pharmasset, Inc. (Acquired by Gilead Sciences) Swiss Pharma Contract (Acquired by Covance) Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI)
Dr. Christine Brennan is a Principal in Cambridge, MA, USA. Prior to joining Novartis Venture Fund, she was Chief Business Officer at Vitae Pharmaceuticals. Previously, she was Executive Director and Head of Strategy & Operations in Strategic Alliances with Novartis Institutes of Biomedical Research and, before that, she has held positions in biotechnology and mid-size pharma companies in business development and marketing at EnVivo Pharmaceuticals, Biovail Corp. and Cogent Neurosciences and was a Director at the venture capital company Fidelity Biosciences Group. She received her PhD in neuroscience from Dartmouth Medical School and completed a postdoctoral fellowship in developmental neurobiology at the National Institutes of Health.
Bart Dzikowski is the Head of Legal for Novartis Venture Fund in Basel, Switzerland. During his time with Novartis, Bart has served as the Head of Corporate Legal M&A (AI) and as Senior Business Development & Licensing / M&A Counsel. Before joining Novartis in 2009, Bart was Vice President with the Investment Banking Division of Bank of America / Merrill Lynch in New York and, before that, he was an associate with the Corporate / M&A Group at the law firm of Allen & Overy LLP in New York. Bart holds degrees in common law (LL.B.) and civil law (B.C.L.) from McGill Law School in Canada and is a member of the New York State bar.
Giovanni Ferrara is a Venture Partner in Cambridge, MA, USA. Prior to joining Novartis Venture Fund, he was a consultant to leading west coast venture capital firms and portfolio companies. Most recently, he was consulting Chief Business Officer to Sorbent Therapeutics. Previously, he was Managing Director and General Partner at Burrill & Company and began his venture capital career at GeneChem Management, where in addition to investing, he held operating positions in portfolio companies, including CEO of Targanta Therapeutics (then PhageTech, Inc.). He began his career in healthcare as a pharmacist at a cancer treatment center researching experimental therapies. He received his MBA and MSc at McGill University. Giovanni serves on the board of Thesan Pharmaceuticals.
Portfolio companies
Thesan Pharmaceuticals, Inc. (Board Seat)
Dr. Markus Goebel is a Managing Director in Basel, Switzerland. Prior to joining Novartis Venture Fund, he worked as head Novartis Pharmaceutical Corporate M&A and Head Nervous System Business Development & Licensing. An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche headquarters before joining Novartis. Markus received an MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley. Markus serves on the boards of eFFECTOR, Ra Pharmaceuticals and Trellis RSV Holdings, Inc.
Portfolio companies
eFFECTOR Therapeutics, Inc. (Board Seat) Ra Pharmaceuticals, Inc. (Board Seat) Trellis RSV Holdings, Inc. (Board Seat)
Exits
Acorda Therapeutics, Inc. (NASDAQ: ACOR) EraGen Biosciences, Inc. (Acquired by Luminex Corporation) FoldRx Pharmaceuticals, Inc. (Acquired by Pfizer) Intellikine, Inc. (Acquired by Takeda) LigoCyte Pharmaceuticals, Inc. (Acquired by Takeda) Sirtris Pharmaceuticals, Inc. (Acquired by GlaxoSmithKline) Xenoport, Inc. (NASDAQ: XNPT)
Florent Gros is a Managing Director in Basel, Switzerland. Prior to joining Novartis Venture Fund, he worked in various global leadership positions in intellectual property and transaction matters at Nestlé, Pasteur Merieux Connaught (Sanofi Pasteur) and Novartis, in Europe and North America. Florent is a Kaufmann Fellow (class 12) and holds a Biotechnology Engineering Master Degree from France, and did his diploma thesis on vaccines at GSK in Belgium. He also holds European and French patent lawyer degrees and a Master in Private Law. Florent serves on the boards of AIT, Atlas Genetics, Gensight Biologics, Immune Targeting Systems, Merus, MyoPowers and Opsona.
Portfolio companies
Applied Immune Technologies, Ltd. (Board Seat) Atlas Genetics, Ltd (Board Seat) Gensight Biologics (Board Seat) Immune Targeting Systems, Ltd. (Board Seat) Merus Biopharmaceuticals BV (Board Seat) MyoPowers Medical Technologies SA (Board Seat) Opsona, Ltd (Board Seat)
Exits
Evolva AG (SIX Swiss Exchange: EVE) Neovacs SA (Alternext Paris: ALNEV) Okairos AG (Acquired by GlaxoSmithKline) Cellerix BV (Merger with Tigenix BV, NYSE Euronext: TIG)
Dr. Anja König is a Managing Director in Basel, Switzerland. She is active in the UK, Switzerland and the rest of Europe. Prior to joining Novartis Venture Fund she was an Associate Partner at McKinsey and Company in New York, a global consultancy, where she worked with healthcare companies in the US, Europe and Emerging Markets. Anja holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle Therapeutics, F2G, Forendo Pharma and Heptares Therapeutics.
Portfolio companies
Bicycle Therapeutics, Ltd. (Board Seat) F2G, Ltd. (Board Seat) Forendo Pharma, Ltd. (Board Seat) Heptares Therapeutics, Ltd. (Board Seat)
Exits
Covagen AG (Acquired by J&J)
Dr. Campbell Murray is a Managing Director in Cambridge, MA, USA. Prior to joining Novartis Venture Fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, Annexon Neurosciences, BioNano Genomics, Euthymics, Galera, ImaginAb and Neurovance.
Portfolio companies
Aerpio Therapeutics, Inc. (Board Seat) Annexon Neurosciences, Inc. (Board Seat) BioNano Genomics, Inc. (Board Seat) Euthymics Bioscience, Inc. (Board Seat) Galera Therapeutics, Inc. (Board Seat) ImaginAb, Inc. (Board Seat) Neurovance, Inc. (Board Seat)
Exits
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Alios BioPharma, Inc. (Acquired by J&J) Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI)
Dr. Henry Skinner is a Managing Director in Cambridge, MA, USA. Prior to joining Novartis Venture Fund he worked as Executive Director & Global Head Strategic Alliances, Therapeutics and Technologies at the Novartis Institutes for Biomedical Research where he led a team responsible for identification, negotiation and management of collaborations and licenses for Novartis’ therapeutic areas as well as technology areas. Prior to joining Novartis he was CEO of SelectX Pharmaceuticals and President and CEO of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was also Director of Technology Acquisitions for Pharmacia & Upjohn and managed business development and licensing for Pharmacia’s research platforms and therapeutic areas worldwide. Prior to Pharmacia he was Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics and earned his PhD in Microbiology and MS in Biochemistry from the University of Illinois. Henry serves on the boards of Adenosine Therapeutics, Aeglea, AMP Therapeutics, Galera Therapeutics, Proteostasis and Quartet Medicine.
Portfolio companies
Aeglea Biotherapeutics Holdings, LLC (Board Seat) AMP Therapeutics GmbH (Board Seat) Galera Therapeutics, Inc. (Board Seat) Proteostasis Therapeutics, Inc. (Board Seat) Quartet Medicine, Inc. (Board Seat)
Exits
Adenosine Therapeutics, Inc. (Acquired by Clinical Data) Avila Therapeutics, Inc. (Acquired by Celgene)
Dr. Lauren Silverman is a Managing Director in Cambridge, MA, USA. Prior to joining Novartis Venture Fund, she was Global Head of Oncology Research Operations for Novartis Institutes for Biomedical Research. Prior to Novartis, she was Director of Business Development and Licensing at Pfizer and OSI Pharmaceuticals. Lauren was also a founding scientist of Cadus Pharmaceuticals. She earned her PhD in molecular biology from the University of Utah, followed by fellowships at Princeton and Memorial Sloan Kettering.
Exits
Celladon, Corp. (NASDAQ: CLDN) Cequent Pharmaceuticals (Acquired by MDRNA)
Steven D. Weinstein is a Managing Director in Cambridge, MA, USA. Steve focuses on both medical device and therapeutic investments for the fund. Steve has been an entrepreneur and venture capitalist for over twenty years, working across bio/pharma, medical device, software, and industrial markets. Prior to joining Novartis Venture Fund, Steve was a Principal at Prism Venture Partners where he focused on medical devices. Prior to Prism, Steve was a Principal and Kauffman Fellow with Mid-Atlantic Venture Fund. He started his career as turnaround CEO, raising angel funds to buy the assets of a defunct distribution business out of bankruptcy and rebuilding the business over the next several years. Steve holds an MBA with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University's School of Engineering and Applied Science. He serves on the Partner's Healthcare Innovation Advisory Board and the University of Michigan Wolverine Venture Fund Advisory Board. Steve serves on the boards of Advanced Animal Diagnostics, Autonomic Technologies, Innocrin, Intersection Medical, Sonitus Medical and Viamet.
Portfolio companies
Advanced Animal Diagnostics, Inc. (Board Seat) Autonomic Technologies, Inc. (Board Seat) Innocrin Pharmaceuticals Holdings, LLC (Board Seat) Intersection Medical, Inc. (Board Seat) Sonitus Medical, Inc. (Board Seat) Viamet Pharmaceuticals Holdings, LLC (Board Seat)
Exits
Ablation Frontiers, Inc. (Acquired by Medtronic) Visiogen, Inc. (Acquired by Abbott)
Directors of Advisory Board –
President of the Ecole Polytechnique Fédérale de Lausanne (EPFL) and Professor of Neurosciences. Member of the Board of Lonza and the Nestlé Health Science Company.
Professor School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL); former Director of the Swiss Institute for Experimental Cancer Research (ISREC); Director of the National Center of Competence in Research (NCCR) in Molecular Oncology.
Chairman, Novartis Institute for Tropical Diseases.
Chief Financial Officer (CFO) of Novartis and member of the Executive Committee of Novartis (ECN).
Nobel Prize Winner for Chemistry, Collège de France, Paris, Université Louis Pasteur, Strasbourg, France.
Director of Research, Institut Curie, Paris, France.
Chief, Department of Internal Medicine and Specialties, Triemli Hospital Zurich, and Associate Professor, Medical Faculty, University of Geneva.
General Partner at Advent Venture Partners, London, UK.
Professor of Biology, Massachusetts Institute of Technology; Member, Whitehead Institute for Biomedical Research.
Our Portfolio
-2.gif){kind=logo}
http://www.advancedanimaldiagnostics.com
Advanced Animal Diagnostics is an animal health diagnostics company, developing highly accurate, rapid on-farm diagnostics. The QScout® line of on-farm diagnostics will detect disease states at an early stage, and optimize management of the reproductive, nutritional and overall health status of production animals, beginning with the dairy cow. The company’s platform diagnostic technology is designed to enhance the profitability of livestock production, improve animal welfare, and ensure a safe, abundant supply of animal protein.
Aeglea is developing recombinant engineered human enzyme therapies to treat a number of cancer indications such as hepatocellular carcinoma, pancreatic adenocarcinoma, mesothelioma and melanoma. Aeglea’s portfolio of products includes engineered enzymes for the degradation of Arginine, Methionine, Cysteine and Cystine. Each of Aeglea’s products is coupled with a set of predictive biomarkers as part of an overall strategy to drive increased efficacy and patient benefit in a variety of oncology indications with significant unmet clinical need.
Aerpio is developing novel small molecule therapies to treat ophthalmic vascular diseases such as diabetic macular edema. Aerpio’s portfolio includes a broad array of HPTPbeta inhibitors that specifically restore signaling through the TIE2 pathway to promote vascular stabilization, improved endothelial function and reduced inflammation.
Aileron Therapeutics is a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform. Aileron aims to dramatically improve the treatment of a wide range of diseases, including cancer and metabolic and endocrine conditions, and positively impact the lives of millions of patients. Aileron’s lead drug development programs are its p53 reactivator for the treatment of cancer, ALRN-6924, and ALRN-5281, a long-acting, growth hormone releasing factor (GRF) for adult growth hormone deficiency that completed a Phase 1 clinical trial in 2013.
http://www.amp-therapeutics.com/
AMP was founded in 2009 as a spin-out of Prof. Ralf Hoffmann’s laboratory at the University of Leipzig and is developing the next generation of broad-spectrum Gram-negative antibiotics for the treatment of drug-resistant infections. It has been estimated that approximately 30-40% of all hospital-acquired (nosocomial) infections worldwide are caused by Gram-negative bacteria. Gram-negative pathogens are highly genetically flexible and thus develop resistance mechanisms that render most of the current therapies ineffective.
Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic and diagnostic applications. AIT is also focused on identification and validation of novel therapeutic targets.
Atlas Genetics is developing the ioTM platform, a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases using either nucleic acid or immunoassays. The system is in series B development and is fast and ultra-sensitive, making it possible to carry out infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.
Autonomic Technologies (ATI) is developing a miniaturized implantable neurostimulation device to provide rapid relief from the debilitating pain and suffering caused by severe headaches such as cluster headaches and migraines.
http://www.bicycletherapeutics.com
Bicycle has a platform technology to create biotherapeutics combining features of small molecules and biopharmaceuticals. Bicycle Therapeutics is a spin-out from the MRC Laboratory of Molecular Biology based on the work of the founding scientists Sir Gregory Winter and Prof. Christian Heinis.
http://www.bionanogenomics.com/
BioNano Genomics has developed the Irys genome mapping platform using nanochannel technology to visualize whole genomes of any organism, including humans. By capturing extremely long DNA molecules at high resolution (hundreds of kilobases vs. single nucleotides), Irys delivers genome maps that provide novel insight into structural variation, such as translocations, amplifications and deletions, that underlies phenotypic variation. The Irys platform can reveal relevant mutations in complex genomes filling the gap between the available cytogenetics and next-generation sequencing/microarray technologies to further advance genome research.
eFFECTOR is pioneering a new class of small molecule drugs that act by selectively regulating translation (protein synthesis). The company unites novel insights into the mechanisms of translational control with a proven approach to product invention. eFFECTOR is pursuing selective translation regulators to restore homeostasis to the translation landscape, thereby reversing the consequences of disregulation and offering treatment for a variety of serious conditions.
Euthymics Bioscience is a privately held, clinical stage, biotherapeutic company that is focused on developing therapeutics that help patients achieve euthymia, which means "mood in the 'normal' range". The company’s lead compound, amitifadine, is in clinical development for alcohol abuse and depression.
F2G is a UK biotechnology company focused on the discovery and development of novel drugs to treat life threatening fungal diseases. F2G is advancing its F3 series of anti-mould compounds. This is a novel class of anti-fungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant aspergilli and many other important pathogenic moulds.
Forendo Pharma is a drug discovery and development company with core competence in tissue specific regulation of sex hormone effects. Its two first-in-class product candidates are progressing to offer significant therapeutic benefits in men’s and women’s health.
http://www.formatherapeutics.com
Forma targets essential cancer pathways to create small molecule cancer therapies. Forma leverages the integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of drug candidates with qualified cellular mechanisms of action. Forma is building a robust pipeline of cancer therapies in areas such as tumor metabolism, protein-protein interactions and epigenetics.
Galera is a clinical stage drug development company with a portfolio of small molecule superoxide dismutase activators. Superoxide, a product of normal cellular oxygen metabolism and certain environmental stresses, is harmful to DNA, RNA, proteins and lipids. This highly reactive molecule is managed by superoxide dismutases (SODs), but the SOD enzyme is deficient in certain disease states. Galera’s technology replaces this loss of function. The company is initially focusing on radiation-induced mucositis, cancer and pulmonary fibrosis.
Genedata provides computational solutions for drug discovery and systems biology research with a combination of software products and professional services that have been developed in partnership with major pharmaceutical and biotechnology companies.
http://www.gensight-biologics.com
GenSight Biologics is focused on the development of gene therapies in ophthalmic diseases to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
Heptares is a drug discovery company which applies structural knowledge of G-protein coupled receptors (GPCRs) to the design and development of proprietary drugs for cardiovascular and CNS diseases. Heptares is a spin-out from the MRC Laboratory of Molecular Biology, based on the pioneering work of the founding scientists Richard Henderson and Chris Tate as well as a wider group of MRC scientists, including Gebhard Schertler and Ed Hulme of the National Institute of Medical Research.
ImagineAb’s has a proprietary antibody fragment platform that yields molecular information to guide treatment decisions in cancer and immunology by in vivo imaging. ImaginAb also collaborates with biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies.
Immune Targeting Systems (ITS) is developing vaccines for mutating viruses and for immunotherapy in oncology. ITS has Phase 2 challenge studies ongoing for influenza and is ready to begin a Hepatitis B therapeutic vaccine clinical study.
Innocrin is a clinical stage pharmaceutical company developing novel, “best-in-class” oral, CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially other hormonally-driven conditions such as breast cancer, endometriosis, or congenital adrenal hyperlplasia.
http://intersectionmedical.com
Intersection is developing a device to help monitor and manage patients in acute decompensated heart failure. A large and growing cost driver for healthcare systems, acute decompensated heart failure and related hospital readmissions is a growing area of focus globally. Intersection looks to improve patient outcomes, inform the treatment paradigm, and reduce costs for healthcare systems.
Merus leverages its proprietary antibody platform to generate full length bi-specific IgG antibodies (Biclonics®) for oncology. The technology platform leverages fixed VL chains to produce functional monoclonal and bi-specific antibodies in a single cell. Merus has also developed an innovative transgenic mice platform (MeMo®) and state-of-the art phage display libraries of human Fab fragments to generate panels of common light change antibodies.
MyoPowers is developing a class III medical implant for the treatment of severe urinary incontinence in males and females, one of the largest under developed therapeutic areas today. MyoPowers aims to enter into CE-enabling clinical studies in 2014.
Nabriva is a specialist antibiotic company with a pipeline of innovative antibacterials for the treatment of serious infections in humans caused by multi-drug resistant pathogens.
Neomics Co., Ltd. (Neomics) is a drug discovery & diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to Aminoacyl tRNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.
Neurovance is a biopharmaceutical company developing treatments for central nervous system (CNS) disorders. Neurovance’s clinical stage EB-1020 for adult attention deficit hyperactivity disorder (ADHD) is a norepinephrine and dopamine-preferring triple reuptake inhibitor that is expected to be effective for adult ADHD without the addiction potential of other ADHD drugs.
Opsona is a drug development company focused on novel therapeutic and preventative approaches to inflammatory and related diseases. Opsona has a pipeline of therapeutics in advanced preclinical development that modulates the innate immune system, including biologics and small molecules that target TLR-2 and Nalp-3. Opsona has started Phase 2b clinical studies with the TLR-2 mAb to prevent delayed graft function in kidney transplant.
PharmAbcine develops fully human therapeutic monoclonal antibodies for the treatment of cancer and inflammatory diseases. PharmAbcine is a spin-out from Korea Research Institute of Bioscience & Biotechnology (KRIBB).
Proteostasis develops novel, small molecule therapeutics designed to control the body’s protein homeostasis, or Proteostasis Network. These therapeutics are designed to treat multiple genetic and degenerative disorders such as Parkinson’s and cystic fibrosis.
http://www.quartetmedicine.com/
Quartet Medicine is discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells.
Qurient is a spin-off biotechnology company from Institut Pasteur Korea (IP-K) committed to developing novel therapeutics against infectious diseases. Qurient’s main focus is on HIV, HCV and TB infection. Qurient has exclusive rights to develop and commercialize drug candidates discovered with IP-K’s proprietary state-of-the-art technologies including the PhenomicScreen™ and PhenomicID™ platforms.
Ra uses proprietary combinatorial assembly and in vitro display technologies to discover macrocyclic compounds with enhanced bioavailability targeting a wide range of intracellular, cell-surface, and circulating proteins. Ra’s initial focus is on orally available replacements for a variety of marketed biologics, as well as drugs targeting intracellular protein-protein interactions.
Sonitus Medical has developed an FDA approved medical device for the treatment of single-sided deafness and conductive hearing loss using the principal of bone conduction. It is the first non-surgical and removable hearing solution that relies on bone conduction.
Symetis is successfully marketing a transapical catheter-mediated delivery system on the beating heart to insert stented mechanical valves for application in cardiac valve replacement.
Thesan is developing innovative therapeutics for dermatological applications. The company is currently developing topical applications of novel chemical entities against unexplored targets for atopic dermatitis and acne.
Trellis RSV Holdings is leveraging its proprietary CellSpotTM technology to deliver higher quality therapeutic monoclonal antibodies. The company has programs in infectious disease.
Viamet is a clinical stage biotechnology company that discovers and develops “best-in-class” small molecule inhibitors of validated metalloenzymes via an innovative metal binding approach, its proprietary Metallophile® Technology. The company develops traditional small molecule compounds that exploit validated metalloenzyme targets in the field of infectious disease.
Annexon is developing disease modifying therapeutics to protect neuronal connections (synapses) that are lost in nearly all forms of neurodegenerative disease. Annexon's platform is focused on inhibiting C1q as the initiating molecule of the complement cascade responsible for aberrantly binding to functional synapses and triggering their elimination in neurodegenerative disease. This pathway is also well known to contribute to pathology in a number of autoimmune diseases of the nervous system. Annexon’s lead molecule, ANX005, effectively blocks this pathway and will have broad therapeutic application in both acute and chronic neurological diseases. Annexon’s initial focus will be in acute peripheral immune mediated disorders.
